- Conditions
- Ocular Redness
- Interventions
- BTOS-HA, Lumify®
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 11
- States / cities
- Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Erythema, Sensitisation
- Interventions
- Test Article, Negative Control
- Device · Other
- Lead sponsor
- Omeza, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- St. Petersburg, Florida
- Conditions
- Hyperemia
- Interventions
- Brimonidine tartrate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Parvovirus B19 Infection
- Interventions
- VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Cincinnati, Ohio • Houston, Texas
- Conditions
- Allergic Conjunctivitis
- Interventions
- Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%
- Drug
- Lead sponsor
- Eye Therapies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Alveolar Osteitis, Dry Socket, Infection
- Interventions
- IV Preoperative antibiotic or placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Interventions
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Erythema, Rosacea
- Interventions
- CD07805/47 gel 0.5%/CD07805/47 Vehicle, azelaic acid gel 15%
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 4
- States / cities
- Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more
- Conditions
- Erythema Migrans Lesions, Erythema Migrans
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acne Rosacea
- Interventions
- PRK 124
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Rosacea
- Interventions
- CD07805/47 gel 0.5%
- Drug
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 449 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 27
- States / cities
- Santa Monica, California • Denver, Colorado • Longmont, Colorado + 22 more
- Conditions
- Erythema, Rosacea
- Interventions
- Oxymetazoline HCL Cream 1.0%, Vehicle to Oxymetazoline HCL Cream
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 445 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Ecchymosis and Erythema Commonly Associated With Soft Tissue Filler Injections
- Interventions
- Multizyme Cellular Vitality Cyruta Plus SHEP
- Dietary Supplement
- Lead sponsor
- DeNova Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Sickle Cell Disease
- Interventions
- Blood draw, Nasopharyngeal wash
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Erythematotelangiectatic Rosacea
- Interventions
- The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
- Device · Drug
- Lead sponsor
- Candela Corporation
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Houston, Texas
- Conditions
- Stevens-Johnson Syndrome, Corneal Blindness
- Interventions
- Infliximab
- Drug
- Lead sponsor
- Massachusetts Eye and Ear Infirmary
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
- Interventions
- Riboflavin
- Drug
- Lead sponsor
- Joseph B. Ciolino, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Erythema Nodosum Leprosum
- Interventions
- Dovramilast, Prednisolone, Thalidomide
- Drug
- Lead sponsor
- Medicines Development for Global Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Postoperative Care
- Interventions
- capnostream 20, Oridian Medical 1987 ltd, Needham MA
- Device
- Lead sponsor
- Allenmore Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Non-melanomatous Skin Cancer
- Interventions
- celecoxib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, cancer prevention intervention, chemoprevention of cancer, growth factor antagonist therapy
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 20 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Erythema, Edema
- Interventions
- Trojan "Simply Pleasure" Personal Lubricant
- Device
- Lead sponsor
- Church & Dwight Company, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Piscataway, New Jersey
- Conditions
- Rosacea
- Interventions
- Brimonidine, placebo
- Drug
- Lead sponsor
- Actavis Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 16
- States / cities
- Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
- Conditions
- Rosacea
- Interventions
- Pulse Dye Laser/YAG laser
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Rosacea
- Interventions
- CGB-400
- Drug
- Lead sponsor
- CAGE Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Fremont, California • San Diego, California • Edgewater, Florida